NASDAQ: SANASana Biotechnology Inc Stock
$8.58+0.49 (+6.06%)
Updated Apr 24, 2024
SANA Price
$8.58
Fair Value Price
$0.17
Market Cap
$1.89B
52 Week Low
$2.75
52 Week High
$12.00
P/E
-5.88x
P/B
6.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$283.26M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.97
Operating Cash Flow
-$254M
Beta
2.14
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SANA Overview
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SANA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SANA ($8.58) is overvalued by 4,919.58% relative to our estimate of its Fair Value price of $0.17 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SANA ($8.58) is not significantly undervalued (4,919.58%) relative to our estimate of its Fair Value price of $0.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SANA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SANA due diligence checks available for Premium users.
Be the first to know about important SANA news, forecast changes, insider trades & much more!
SANA News
Valuation
SANA fair value
Fair Value of SANA stock based on Discounted Cash Flow (DCF)
Price
$8.58
Fair Value
$0.17
Overvalued by
4,919.58%
SANA ($8.58) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SANA ($8.58) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SANA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SANA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.88x
Industry
15.69x
Market
41.27x
SANA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.58x
Industry
5.86x
SANA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SANA's financial health
Profit margin
Revenue
$0.0
Net Income
-$88.1M
Profit Margin
0%
SANA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$565.3M
Liabilities
$277.8M
Debt to equity
0.97
SANA's short-term assets ($213.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SANA's short-term assets ($213.52M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SANA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SANA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$52.0M
Investing
$15.3M
Financing
$1.7M
SANA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SANA vs Biotech Stocks
Sana Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.